Future prospects of prophylaxis for deep vein thrombosis

Blood Coagulation and Fibrinolysis

Volumn 10, Issue 6 SUPPL. 2, 1999, Pages

  Pini, M ^a  

^a Regione Piemonte USL 49   (Italy)

Author keywords

Danaparoid; Deep vein thrombosis; Desirudin; Hirudin; Low molecular weight heparin; Pentasaccharide; Thrombin inhibitor; Thromboprophylaxis

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; ARGATROBAN; CHONDROITIN SULFATE; DANAPAROID; DERMATAN SULFATE; DESULFATOHIRUDIN; DIHYDROERGOTAMINE; ENOXAPARIN; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEPARIN; HEPARINOID; HIRUDIN; HIRUDIN DERIVATIVE; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PENTASACCHARIDE; THROMBIN INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; WARFARIN;

BLEEDING; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG EMBOLISM; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; POSTTHROMBOSIS SYNDROME; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; THROMBOEMBOLISM;

ANTICOAGULANTS; FORECASTING; HUMANS; PREMEDICATION; THROMBIN; VENOUS THROMBOSIS;

EID: 0032851334     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (60)

1. Nicolaides AN, Bcrgqvist D, Hull R, Ackchurin RS, Allegra C, Arcelus J, et al. Consensus statement: prevention of venous thromboembolism. Int Angiol 1997; 16: 3-38.
2. Turpie AGG. Low-molecular-weight heparin: from the bench to the orthopaedic patient. Orthopedics 1997; 20 (suppl 2): 10-13.
3. Clagett GP, Anderson FA, Heit J, Lavine MN, Wheeler HB. Prevention of venous thromboembolism. Chest 1995; 108 (suppl4): 312S-334S.
4. Hull R, Raskob G, Pineo G, Rosenbloom D, Evans W, Mallory T, et al. A comparison of subcutaneous low molecular weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 1993; 329: 1370-1376.
5. Nurmohamed MT, Rosendaal TR, Büller HR, Dekker E, Hommes DW, Vandenbroucke JP, et al. Low molecular weight heparin versus standard heparin in general and orthopaedic surgery. A meta-analysis. Lancet 1992; 340: 152-156.
6. Boneu B. New antithrombotic agents for the prevention and treatment of deep vein thrombosis. Haemostasis 1996; 26 (suppl 4); 368-378.
7. Hirsh J, Levine M. Low molecular weight heparin. Blood 1992; 79: 1-17.
8. Nelson-Piercy G, Letsky EA, de Swiet M. Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol 1997; 176: 1602-1608.
9. Fareed J, Callas DD, Hoppensteadt DA, Walenga WM, Pifarre R. Current developments in anticoagulant and antithrombotic agents. In: Pifarre R, (editor). New Anticoagulants for the Cardiovascular Patient. Philadelphia,: Hanley & Belfus, Inc., 1997; 95-126.
10. Haas S. Low-molccular-weight heparin in the prevention and management of deep vein thrombosis. In: Pifarre R, Ed. New Anticoagulants for the Cardiovascular Patient. Philadelphia, PA: Hanley & Belfus, Inc., 1997, pp. 127-136.
11. John LCH, Rees GM, Kovacs IB. Inhibition of platelet function by heparin. J Thorac Cardiovasc Surgery 1993; 105:816-822.
12. Jeske W, Pifarre R, Wolf H, Fareed J. An overview of blood coagulation. In: Pifarre R(editor). New Anticoagulants for the Cardiovascular Patient. Philadelphia: Hanley & Belfus, Inc., 1997; 9-38.
13. Herbert JM, Petitou M, Lormeau JC, Cariou R, Necciari J, Magnani HN, et al. SR 90107A/Org 31540, a novel antifactor Xa antithrombotic agent. Cardiovasc Drug Rev 1997; 15: 1-26.
14. Yin ET. Effect of heparin on the neutralization of factor Xa and thrombin by the plasma alpha-II globulin inhibitor. Thromb Diathes Haemorrh 1975; 33: 43-50.
15. Maffrand JP. Direct thrombin inhibitors. Nouv Rev Fr Hematol 1992; 34: 405-419.
16. Verstraete M. Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins. Drugs 1990; 40; 498-530.
17. Andersson LO, Barrowcliffe TW, Holmer E, Johnson EA, Sims GEC. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration. Thromb Res 1976; 9: 575-583.
18. Hoylaerts M, Owen WG, Collen D. Involvement of heparin chain length in the heparin catalyzed inhibition of thrombin by antithrombin III. J Biol Chem 1984; 259: 5670-5677.
19. Young E, Wells P, Holloway S, Weitz J, Hirsh J. Ex-vivo and in-vitro evidence that low molecular weight hcparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost 1994; 71: 300-304.
20. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts PS, Gent M, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular weight heparin or unfractionated heparin. N Eng!J Med 1995; 332: 1330-1335.
21. Verhamme IMA, van Dedem GWK. Effect of the buffer composition and the presence of ORG 10172 and some glycosaminoglycans on the inhibition of alpha-thrombin by heparin cofactor II. Thromb Haemost 1987; 58: 422 (Abstract).
22. Magnani HN, Beijering RJR, ten Cate JW, Chong BH. Orgaran anticoagulation for cardiopulmonary bypass in patients with heparin-induced thrombocytopcnia. In: Pifarre R(editor). New Anticoagulants for the Cardiovascular Patient. Philadelphia: Hanley & Belfus, Inc., 1997; 487-500.
23. Sinay P, Jacquinet J, Pctitou M, Duchaussoy P, Lederman I, Choay J, et al. Total synthesis of a heparin pcntasaccharidc fragment having high affinity for antithrombin III. Carbohydrate Res 1984; 132: C5-C9.
24. Tollefsen DM, Petska CA, Monafo WJ. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 1983; 258: 6713-6716.
25. Dol F, Houin G, Rostin M, Montastruc JL, Dupouy D, Gianese F, et al. Pharmacokinetics and pharmacodynamics of dermatan sulphate in humans. Blood 1989; 74: 1577-1582.
26. Dol F, Petitou M, Lormeau JG, Caranobe C, Sie P, Saivin S, et al. Pharmacological properties of a low molecular weight dermatan sulfate: comparison with unfractionated dermatan sulfate. J Lab Clin Med 1990; 115: 43-51.
27. Rosenberg RD. The heparin-antithrombin system: a natural anticoagulation mechanism. In Colman RW, Hirsh J, Marder VJ, Salzman EX(editors). Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia: Lippincott, 1987; 1373-1392.
28. Eschenfelder V. Pharmacologic considerations in the development of hirudin and its derivatives for cardiovascular indications. In: Pifarre R, Ed. New Anticoagulants for the Cardiovascular Patient, Philadelphia: Hanley & Belfus, Inc., 1997; 161-174.
29. Loscalzo J, Melnick B, Handin R. The interaction of platelet factor 4 and glycosaminoglycans. Arch Biochem Biopbys 1985; 240: 446-455.
30. Agnelli G, Sonaglia F. Recombinant hirudin in the prevention of venous thromboembolism in patients undergoing elective hip surgery. Semin Thromb Hemost 1997; 23: 143-148.
31. Markwardt F. Development of hirudin as an antithrombotic agent. Semin Thromb Hemost 1989; 15: 269-282.
32. Maraganore JM, Chao B, Joseph ML, Jablonski J, Ramachandran KL. Anticoagulant activity of synthetic hirudin fragments. J Biol Chem 1989; 264: 8692-8698.
33. Esslinger HU, Haas S, Lassmann A, Stemberger A, Baumgartner M, Blumel G, et al. Phase I results on PEG-hirudin (Lu 57291), a safe and effective anticoagulant with prolonged activity. Thromb Haemost 1995; 73: 1452 (Abstract).
34. Kelly AB, Maraganore JM, Bourdon P, Hanson SR, Harker LA. Anithrombotic effects of synthetic peptidcs targeting different functional domains of thrombin. Proc Natl Acad Sci USA 1992; 89: 6040-6044.
35. Leyvraz P, Bachmann V, Bohnet J, Breyer HG, Estoppey D, Haas S, et al. Thromboembolic prophylaxis in total hip replacement: a comparison between the low molecular weight heparinoid lomoparan and heparin-dihydroergotamine. Br J Surg 1992; 79: 911-914.
36. Gerhart TN, Yett HS, Robertson LK, Lee MA, Smith M, Salzman EW. Low molecular weight heparinoid compared with warfarin for prophylaxis of deep-vein thrombosis in patients who are operated on for fracture of the hip. J Bone Joint Surg 1991; 73A: 494-502.
37. Gallus A, Cade J, Ockclford P, Hepburn S, Maas M, Magnani H, et al. Orgaran (Org 10172) or heparin for preventing venous thrombosis after elective surgery for malignant disease. Thromb Haemost 1993; 70: 562-567.
38. Turpie AGG. Orgaran in the prevention of deep vein thrombosis in stroke patients. Haemostasis 1992; 22: 92-98.
39. Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemost 1993; 70: 554-561.
40. Turpie AGG, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, et al. Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. Lancet 1987; i: 523-526.
41. Sherman DG. Heparin and heparinoids in stroke. Neurology 1998; 51: S56-S58.
42. Chong BH, Magnani HN. Orgaran in heparin-induced thrombocytopenia. Haemostasis 1992; 22: 85-91.
43. Amiral J, Lormeau JC, Marfaing-Koka A, Vissac AM, Wolf M, Boyer-Neumann C, et al. Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coag Fibrinol 1997; 8: 114-117.
44. Cohen AT, Phillips MJ, Edmonson RA, Skinner JA, Das SK, Cooper DJ, et al. A dose ranging study to evaluate dermatan sulphate in preventing deep vein thrombosis following total hip arthroplasty. Thromb Haemost 1994; 72: 793-798.
45. Agnelli G, Cosmi B, Di Fillipo P, Ranucci V, Veschi F, Longetti M, et al. A randomized double-blind, placebo-controlled trial of dermatan sulphate for prevention of deep vein thrombosis in hip fracture. Thromb Haemost 1992; 67: 203-208.
46. Di Carlo V, Mannucci PM, Agnelli G, Coccheri S, Gensini GF, Prandoni P. Dermatan sulfate for the prevention of post-operative venous thromboembolism in cancer patients. Thromb Res 1998; 91 (suppl 1): S52 (Abstract).
47. Greinacher A, Volpd II, Poetzsch B. Recombinant hirudin (HBW 023) in the treatment of patients with heparin-associated thrombocytopenia (HAT) -A prospective study. Thromb Haemost 1995; 73: Abstract 2124.
48. Schiele F, Vuillemenot A, Kramarz P, Kieffer Y, Bassand JP, Antithrombotic treatment with recombinant hirudin in patients with heparin-induced thrombocytopenia. Thromb Haemost 1995; 73: Abstract 2123.
49. Zeymer U, Mateblowski M, Neuhaus K-L. Recombinant hirudin (HBW 023) produces stable anticoagulation unaffected by circadian variation in patients with thrombolysis for acute myocardial infarction. Eur Heart J 1996; 17: 1836-1840.
50. Fox KAA. r-Hirudin in unstable angina pectoris. Rationale and preliminary data from the APT pilot study. Eur Heart J 1995; 16(suppl D): 28-32.
51. Rupprecht HJ, Terres W, Ozbek C, Luz M, Jessel A, Hafner G, et al. Recombinant hirudin (HBW 023) prevents troponin T release after coronary angioplasty in patients with unstable angina. J Am Coll Cardiol 1995; 26: 1637-1642.
52. Schiele F, Lindgaerde F, Eriksson H, Bassand JP, Wallmark A, Hansson PO, et al. Subcutaneous recombinant hirudin (HBW-023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: A multicentre prospective dose-ranging randomised trial. Thromb Haemost 1997; 77: 834-838.
53. Eriksson BI, Ekman S, Kalebo P, Zachrisson B, Bach D, Close P. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet 1996; 347: 635-639.
54. Eriksson BI, Ekman S, Lindbratt S, Baur M, Bach D, Torhom C, et al. Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. J Bone Joint Surg 1997; 79: 326-333.
55. Eriksson BI, Wille-Jøsrgensen P, Kalebo P, Mouret P, Rosencher N, Bosch P, et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997; 337: 1329-1335.
56. van den Bos AA, Deckers JW, Heyndrickx GR, Laarman CJ, Suryapranata H, Zijlstra F, et al. Safety and efficacy of recombinant hirudin (CGP 39393) versus heparin in patients with stable angina undergoing coronary angioplasty. Circulation 1993; 88: 2058-2066.
57. Topol FJ, Fuster V, Harrington RA, Califf RM, Kleinmann NS, Kercikas DJ, et al. Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial. Circulation 1994; 89: 1557-1566.
58. Cannon CP, McCabe CH, Henry TD, Schewieger MJ, Gibson RS, Mueller HS, et al. for the TIMI-5 investigators. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acme myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol 1994; 23: 993-1003.
59. Serruys PW, Fox KAA, Herrman JPR, Bach D, Close P, Deckers J, HELVETICA Investigators. Recombinant hirudin (CGP 39393) reduces the incidence of major adverse cardiac events, reported within the first 96 hours post angioplasty in unstable patients (Braunwald classification) pretreated by heparin. J Am Coll Cardiol 1995; 23: 90A (Abstract).
60. Drummond M, Aristides M, Davies L, Forbes C. Economic evaluation of standard heparin and enoxaparin for prophylaxis against deep vein thrombosis in elective hip surgery. Br J Surg 1994; 81: 1742-1746.